LDN-212320 (10 or 20 mg/kg, i.p) significantly attenuates formalin-evoked nociceptive behavior[1].
LDN-212320 (10 or 20 mg/kg, i.p) significantly reverses formalin-induced impaired hippocampal-dependent behavior. In addition, LDN-212320 (10 or 20 mg/kg, i.p) increases GLT-1 expressions in the hippocampus and ACC[1].
LDN-212320 (20 mg/kg, i.p) significantly reduced formalin induced-ERK phosphorylation, a marker of nociception, in the hippocampus and ACC[1].
| Animal Model: | Mice[1]. |
| Dosage: | 10 or 20 mg/kg. |
| Administration: | IP 24 h before the injection of formalin. |
| Result: | Significantly attenuated licking and biting behavior during both phases 1 and 2 in a dose-dependent manner compared to formalin-injected mice.
Significantly (P < 0.01 or P < 0.001) reduced the licking and biting behavior.
Significantly increased preference for the displaced object (F3, 13 = 28.03, P < 0.01) compared to formalin-injected mice.
Significantly (P < 0.001) increased interaction time with the displaced object compared to formalin-injected mice.
|
